Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer

Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer Background:Gemcitabine is the standard chemotherapy for the treatment of advanced pancreatic cancer. The novel multitargeted antifolate pemetrexed (Alimta®) has also demonstrated activity in this disease. These two drugs are synergistic in vitro, and a phase I study has demonstrated activity of single-agent pemetrexed in pancreatic cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Phase II Study of Pemetrexed Plus Gemcitabine in Advanced Pancreatic Cancer

Loading next page...
 
/lp/springer-journals/phase-ii-study-of-pemetrexed-plus-gemcitabine-in-advanced-pancreatic-ruu9hd2oWD
Publisher
Springer Journals
Copyright
Copyright © 2005 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200504030-00005
Publisher site
See Article on Publisher Site

Abstract

Background:Gemcitabine is the standard chemotherapy for the treatment of advanced pancreatic cancer. The novel multitargeted antifolate pemetrexed (Alimta®) has also demonstrated activity in this disease. These two drugs are synergistic in vitro, and a phase I study has demonstrated activity of single-agent pemetrexed in pancreatic cancer.

Journal

American Journal of CancerSpringer Journals

Published: Aug 10, 2012

References